Needham Maintains Buy on Evolent Health, Lowers Price Target to $4
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $15 to $4.
Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $15 to $4.